CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025. Revenue increased 89.6% year-over-year to $314.6 million in the second quarter Genomics revenue increased 115.3% year-over-year to $241.8 million on accelerating year-over-year volume growth in Oncology (26%) and Hereditary (32%) testing Data and services revenue increased 35
Related Questions
What guidance, if any, has Tempus provided for Q3 and Q4 2025, and how reliable is it?
What is the breakdown of the 115.3% YoY increase in Genomics revenue between Oncology and Hereditary testing?
Is the 26% YoY volume growth in Oncology testing sustainable, and what market factors could influence it?
How does Tempus' Q2 2025 performance compare to its peers in the AI-driven precision medicine space?
Are there any upcoming regulatory or reimbursement changes that could affect Tempus' revenue streams?
What impact could this earnings beat have on short‑term trading volume and volatility of TEM stock?
How will Tempus AI's 89.6% YoY revenue growth affect its valuation and price target?
What is the cash burn rate given the rapid growth, and does the company have sufficient liquidity to fund expansion?
What are the margins on the Genomics and Data & Services segments, and how might they impact profitability?
How might the 35% increase in Data and Services revenue translate into recurring revenue and long‑term contracts?